NASDAQ:CADL • US1374041093
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for CANDEL THERAPEUTICS INC (CADL).
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2026-04-20 | Cantor Fitzgerald | Initiate | Overweight |
| 2026-03-18 | Citigroup | Maintains | Buy -> Buy |
| 2026-03-13 | Canaccord Genuity | Maintains | Buy -> Buy |
| 2026-03-13 | Citigroup | Maintains | Buy -> Buy |
| 2025-12-08 | Stephens & Co. | Reiterate | Overweight -> Overweight |
| 2025-11-14 | Citigroup | Maintains | Buy -> Buy |
| 2025-10-28 | Stephens & Co. | Initiate | Overweight |
| 2025-10-21 | LifeSci Capital | Initiate | Outperform |
| 2025-09-29 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-09-03 | B of A Securities | Downgrade | Buy -> Neutral |
| 2025-04-11 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-03-14 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-02-26 | Canaccord Genuity | Maintains | Buy -> Buy |
| 2025-02-26 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-02-20 | Citigroup | Initiate | Buy |
| 2025-02-19 | Canaccord Genuity | Initiate | Buy |
| 2025-02-07 | B of A Securities | Initiate | Buy |
| 2024-12-18 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-11-18 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2023-11-13 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2023-05-22 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2023-05-15 | BMO Capital | Maintains | Outperform -> Outperform |
| 2023-03-31 | Credit Suisse | Maintains | Outperform |
| 2022-12-07 | Credit Suisse | Maintains | Outperform |
| 2022-12-02 | HC Wainwright & Co. | Initiate | Buy |
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 125K | 125K | 125K | -100.00% | 57.567M | 252.94M 339.38% | 485.7M 92.02% | 811.75M 67.13% | 909.97M 12.10% | 1.203B 32.20% | 1.485B 23.44% | ||||
| EBITDA YoY % growth | -13.719M -52.54% | -25.494M -85.83% | -33.944M -33.15% | -34.996M -9.09% | -35.067M 12.56% | -46.695M -44.20% | -75.967M -62.69% | -46.458M 38.84% | 92.128M 298.31% | 668.02M 625.10% | 1.201B 79.79% | 55.386M -95.39% | N/A | N/A | |
| EBIT YoY % growth | -13.81M -52.82% | -25.726M -86.29% | -34.722M -34.97% | -38.046M -9.41% | -35.512M 12.16% | -47.244M -41.57% | -72.535M -53.53% | -39.524M 45.51% | 55.469M 240.34% | 350.86M 532.53% | 613.07M 74.73% | 478.33M -21.98% | 646.36M 35.13% | 796.27M 23.19% | |
| Operating Margin | -11,048.00% | -20,580.80% | -27,777.60% | N/A | N/A | N/A | N/A | -68.66% | 21.93% | 72.24% | 75.52% | 52.57% | 53.73% | 53.62% | |
| EPS YoY % growth | N/A | N/A | -1.12 46.21% | -1.11 -21.43% | -1.40 -2.69% | -0.43 49.16% | -1.32 -85.99% | -0.75 42.83% | 0.81 207.65% | N/A | N/A | N/A | N/A | N/A |
All data in USD
| Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | |
|---|---|---|---|---|
| EPS Q2Q % growth | -0.34 -360.65% | -0.35 -287.60% | -0.37 -74.47% | -0.38 29.51% |
| Revenue Q2Q % growth | ||||
| EBITDA Q2Q % growth | -16.821M -113.32% | -17.618M -64.81% | -19.563M -60.03% | -21.118M -41.66% |
| EBIT Q2Q % growth | -16.974M -108.78% | -17.685M -58.22% | -19.368M -50.05% | -20.751M -31.73% |
All data in USD
14 analysts have analysed CADL and the average price target is 19.25 USD. This implies a price increase of 173.47% is expected in the next year compared to the current price of 7.04.
CANDEL THERAPEUTICS INC (CADL) will report earnings on 2026-05-11.
The consensus EPS estimate for the next earnings of CANDEL THERAPEUTICS INC (CADL) is -0.34 USD and the consensus revenue estimate is 0 USD.